anti-CD30 antibody drug conjugate (NBE-Therapeutics)

N/A

Report date: 2025/03/14 16:31:36

Base Information

Drug Nameanti-CD30 antibody drug conjugate (NBE-Therapeutics)

Drug Alias NameN/A

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitors

TargetsTumor necrosis factor receptor superfamily member 8

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySwitzerland

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesNbe-Therapeutics Ag

China Registration ClassN/A

Inactive CompaniesN/A

Active IndicationsNeoplasms

Inactive IndicationsN/A

ATC CodeN/A